Biotech City The director of Biotech City in Laval, close to Montreal, discusses the advantages brought on by the cluster effect, and how this has played out at Biotech City, a government funded cluster of 80 companies and over 5,000 employees. Your background has a strong focus on business start-ups and development,…
Bavarian Nordic If there is one thing that successful Danish companies have in common with one another, it is the clear recognition of abundant opportunities outside the motherland. “Danish companies’ strengths lie in their ability to build on what they have inherited from Denmark but to also look outward and be…
investment The CEO of one of Denmark’s largest foundations talks about the merits of the foundation model, and the current strategies of both Lundbeck and ALK in the areas of diversification, internationalization of R&D, and what it means to be a Danish company. The end of the blockbuster era has put…
Biotechnology The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic shift towards becoming a semi-virtual model company. He also considers the importance of creating global links to capital as a…
investment The CEO of MaRS Innovation, a commercialization incubator created by 16 of Toronto’s best research institutions and supported by the government, assesses Toronto’s merits as an innovation hub, and describes several successful case studies of the way in which MaRS Innovation has helped to commercialize ideas in the pharmaceutical and…
government relations Minister Marceau addresses the changes in policy in Quebec relating to the pharmaceutical and life sciences sectors, and the incentives in place to make the state an attractive place for the future of the pharmaceutical industry. According to the Economic and Financial Profile of Quebec 2012, Quebec allocated 2.61…
government relations A perspective from Canada’s national health body on the future of medicine in the 21st century, from the shift to personalized medicine to streamlining regulatory and approval processes, removing duplication from international partners and utilizing modern communications technology to improve transparency and efficiency. Could you provide a brief overview of…
Basic Research A leading figure in the Taiwanese pharmaceutical sector, Lee divulges the practicalities behind ECFA, the free trade agreement that was signed between China and Taiwan in 2010 but has not yet come into full force; questions whether a lack of multinational investment has been a major disadvantage for Taiwan; explains…
government relations Under the administration of President Juan Manuel Santos, Colombia is focusing on bolstering the commercial sector. Thanks to the ratification of free trade agreements with 14 countries around the world since 2011, including the United States, foreign direct investment reached a record high of COP 29 trillion ($16 billion)…
drug development BIOTECanada is the national trade association for Canada’s biotech industry. Andrew Casey, the group’s CEO, discusses the impact of IP regulation on emerging biotech companies, incentives for developing the sector on a national level, and offers perspectives on tax policy and its impact on drug development. How does BIOTECanada actively…
Ireland What makes Ireland attractive for FDI? As the former general manager of Genzyme’s Waterford site, Pat O’Sullivan explains that a longstanding 12.5% corporate tax rate (that isn’t going anywhere) is one factor, but it doesn’t end there. Talent: “The first factor is the excellence of the workforce, which is…
Contract Manufacturing Lilly set up in Ireland three decades ago by purchasing a farm. In its early days, the operation produced intermediaries for small-molecule drugs. Nearby, Pfizer was manufacturing citric acid for soft drinks. The country was a fledgling industrial economy that was still mostly reliant on sectors like agriculture and fishing.…
See our Cookie Privacy Policy Here